NPM1 and neoplasm: Moreover, van der Lee et al., documented immune responses and isolated CLAVEEVSL-specific TCR from HLA-A*02:01-positive healthy individuals, suggesting that high-affinity T cells against neoantigens arising from tumor-specific molecular lesions, such as NPM1 mutations, which are absent in healthy tissues, are therefore not deleted by thymic selection through T-cell maturation processes [20,51,52].